MetaVia shares are trading higher after the company announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel.

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!